Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 242Lymphoma 237Lymphoma, Non-Hodgkin 206Leukemia, Lymphocytic, Chronic, B-Cell 186Lymphoma, Large B-Cell, Diffuse 179Lymphoma, Follicular 175Lymphoma, B-Cell 113Lymphoma, Mantle-Cell 107Hodgkin Disease 105Leukemia, Myeloid, Acute 102Recurrence 98Multiple Myeloma 92Burkitt Lymphoma 90Leukemia 78Neoplasms 68Lymphoma, B-Cell, Marginal Zone 60Hematologic Neoplasms 59Myelodysplastic Syndromes 56Waldenstrom Macroglobulinemia 48Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, T-Cell 43Lymphoma, T-Cell, Peripheral 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Biphenotypic, Acute 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Leukemia, B-Cell 27Mycosis Fungoides 25Lymphoma, Large-Cell, Anaplastic 25Sarcoma 24Breast Neoplasms 22

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphomatoid Papulosis × Lymphoid × 90 days × Clear all
NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
58 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡